

Ortivus announces that Ponderus Invest AB publishes the offer document regarding the mandatory cash offer to the shareholders of Ortivus

Ponderus Invest AB ("Ponderus") announced on 2 December 2025 a mandatory cash offer to the shareholders of Ortivus Aktiebolag ("Ortivus") to transfer all of their shares in Ortivus to Ponderus for SEK 1.22 per class A share and class B share, respectively (the "Offer"). The Offer was made in accordance with the Takeover Rules for Certain Trading Platforms issued by the Swedish Securities Council's Self-Regulatory Committee, dated 1 July 2025.

Ortivus hereby announces that Ponderus today publishes the offer document for the Offer (the "Offer Document"). The Offer Document is available on Ponderus' website (www.ponderusinvest.se) and on Nordic Issuing's website (www.nordic-issuing.se).

The acceptance period for the Offer runs from 15 December 2025 up to and including 12 January 2026. Payment of the consideration is expected to commence on or about 19 January 2026. Ponderus reserves the right to extend the acceptance period and to postpone the date for payment of the consideration in respect of the Offer, provided that the date for payment of the consideration to shareholders who have already accepted the Offer is not postponed.

Contacts

For further information, please contact

Gustaf Nordenhök, CEO

Phone +46 8 446 45 00

About Ortivus

Ortivus has extensive experience in mobile communication solutions and a unique understanding of clinical healthcare. We develop interactive and user-friendly solutions that support diagnostics, increase efficiency, and deliver long-term cost savings for healthcare providers. By integrating our solutions with electronic health records, dispatch systems, and national registries, we ensure fast and secure information management, a crucial factor in creating a more integrated care process.

Our solutions save valuable time for healthcare professionals, optimise resource use, and reduce the need for avoidable patient transports, resulting in more cost-effective and patient-centred care. With our combination of advanced technology and deep clinical expertise, we support our customers in meeting the healthcare challenges of today and tomorrow.

Ortivus Class A and Class B shares are listed on the NASDAQ First North Growth Market and the company's Certified Adviser is FNCA Sweden AB.

Read more about our solutions at www.ortivus.com

Attachments

[Ortivus announces that Ponderus Invest AB publishes the offer document regarding the mandatory cash offer to the shareholders of Ortivus](#)